Alnylam Pharmaceuticals, Inc. (ALNY) — Stock Valuation & Research

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company primarily dedicated to the discovery, development, and commercialization of innovative therapeutic solutions leveraging ribonucleic acid interference (RNAi) technology. Its robust pipeline of RNAi-based treatments addresses a range of critical therapeutic areas, including inherited genetic disorders, cardio-metabolic conditions, hepatic infectious diseases, and central nervous system (CNS) and ocular disorders. Currently, Alnylam offers several approved therapies: ONPATTRO (patisiran) for adults suffering from polyneuropathy…

ALNY key statistics

Price$160.43
Market cap$21.49B
SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
52-week range156-479.79
Beta0.27

Explore ALNY's full valuation scorecard, price history, financial statements, insider and institutional ownership, and peer comparison on this page — free, no login required.